Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19 a Single-center, Prospective, Randomised Clinical Trial
Latest Information Update: 07 Mar 2023
At a glance
- Drugs Allogeneic dental pulp mesenchymal stem cell therapy Beijing SH Bio-Tech Corporation/Utooth Biological Technology (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
Most Recent Events
- 08 Mar 2021 Planned End Date changed from 31 Mar 2021 to 31 Dec 2021.
- 08 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 30 Nov 2021.
- 14 Apr 2020 New trial record